Bioporto A/S
OTC:THOXF

Watchlist Manager
Bioporto A/S Logo
Bioporto A/S
OTC:THOXF
Watchlist
Price: 0.288 USD Market Closed
Market Cap: $123.7m

Net Margin

-237.4%
Current
Declining
by 24.8%
vs 3-y average of -212.6%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-237.4%
=
Net Income
kr-86.8m
/
Revenue
kr36.6m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-237.4%
=
Net Income
$-86.8m
/
Revenue
kr36.6m

Peer Comparison

Country Company Market Cap Net
Margin
DK
Bioporto A/S
CSE:BIOPOR
458.3m DKK
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
387.5B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
185.5B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
168.8B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
119B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.3B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
42.3B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.2B USD
Loading...

Market Distribution

Lower than 96% of companies in Denmark
Percentile
4rd
Based on 559 companies
4rd percentile
-237.4%
Low
-18 280.1% — 1.4%
Typical Range
1.4% — 15.8%
High
15.8% — 2 389.6%
Distribution Statistics
Denmark
Min -18 280.1%
30th Percentile 1.4%
Median 3.9%
70th Percentile 15.8%
Max 2 389.6%

Bioporto A/S
Glance View

Market Cap
123.7m USD
Industry
Biotechnology

Bioporto A/S engages in the provision of diagnostic tests and antibodies to healthcare professionals in clinical and research settings. The Company’s portfolio comprises five product categories: The Neutrophil gelatinase-associated lipocalin (NGAL) Test, which is a test for diagnosing acute kidney injury; NGAL Enzyme-linked immunosorbent assay (ELISA) kits, which supplies NGAL for the development of medicines for estimating side-effects that are harmful to kidneys; Mannan-binding Lectin (MBL) ELISA kit, which offers monoclonal MBL antibodies that are responsible for the activation of immune response; Antibodies, including monoclonal antibodies used in a range of research areas, such as microbiology, biomarkers, peptide hormones and plasma proteins; and Activated Protein C with Protein C Inhibitor Complex (APC-PCI), a biomarker applied to patients with sepsis and thrombotic and hemostatic disorders. In addition, the Company is a parent of BioPorto Diagnostics A/S.

THOXF Intrinsic Value
0.295 USD
Undervaluation 2%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-237.4%
=
Net Income
kr-86.8m
/
Revenue
kr36.6m
What is Bioporto A/S's current Net Margin?

The current Net Margin for Bioporto A/S is -237.4%, which is below its 3-year median of -212.6%.

How has Net Margin changed over time?

Over the last 3 years, Bioporto A/S’s Net Margin has increased from -250.1% to -237.4%. During this period, it reached a low of -262.1% on Dec 31, 2022 and a high of -147.8% on Jun 30, 2024.

Back to Top